CORVUS PHARMACEUTICALS INC's ticker is CRVS and the CUSIP is 221015100. A total of 62 filers reported holding CORVUS PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $336,000 | -71.5% | 83,607 | -74.0% | 0.03% | -76.7% |
| Q4 2018 | $1,180,000 | -57.2% | 321,430 | 0.0% | 0.13% | -58.0% |
| Q3 2018 | $2,758,000 | -25.2% | 321,430 | -4.3% | 0.32% | -37.7% |
| Q2 2018 | $3,689,000 | -0.5% | 335,987 | +4.5% | 0.51% | -9.6% |
| Q1 2018 | $3,706,000 | +61.6% | 321,430 | +45.2% | 0.56% | +109.3% |
| Q4 2017 | $2,294,000 | -35.0% | 221,430 | 0.0% | 0.27% | -46.6% |
| Q3 2017 | $3,530,000 | +13.2% | 221,430 | -14.1% | 0.50% | -4.9% |
| Q2 2017 | $3,118,000 | -46.2% | 257,665 | -7.7% | 0.53% | -53.2% |
| Q1 2017 | $5,798,000 | +26.6% | 279,166 | -12.8% | 1.13% | -2.2% |
| Q4 2016 | $4,579,000 | -14.4% | 320,229 | -1.5% | 1.16% | +33.1% |
| Q3 2016 | $5,347,000 | +16.8% | 325,053 | 0.0% | 0.87% | -26.7% |
| Q2 2016 | $4,577,000 | +184.6% | 325,053 | +193.0% | 1.19% | +240.4% |
| Q1 2016 | $1,608,000 | – | 110,921 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADAMS STREET PARTNERS LLC | 3,275,616 | $2,784,274 | 0.93% |
| CHI Advisors LLC | 2,384,402 | $2,026,742 | 0.54% |
| Telemetry Investments, L.L.C. | 390,000 | $332 | 0.52% |
| Orbimed Advisors | 6,943,654 | $5,902,106 | 0.11% |
| DISCOVERY CAPITAL MANAGEMENT, LLC / CT | 548,727 | $466,418 | 0.07% |
| BVF INC/IL | 1,370,947 | $1,165,305 | 0.05% |
| JACKSON SQUARE CAPITAL, LLC | 63,773 | $54,207 | 0.03% |
| Artal Group S.A. | 500,000 | $425 | 0.02% |
| Hikari Power Ltd | 49,959 | $42 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 159,300 | $135,405 | 0.00% |